DrugDashboards

Dobutamine

Dobutamine · DOBUTAMINE HYDROCHLORIDE 12.5 mg/mL · Injection, Solution, Concentrate · Intravenous · Hospira, Inc.

NDC 00409-2344-02 · 10 VIAL, SINGLE-DOSE in 1 TRAY / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “other”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$69.31
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 250 MG
$7.691
HCPCS J1250 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$107,025
916 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA074086
TE code
AP
Approval date
Nov 29, 1993
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)Aug 27, 2025
  • In shortage now — Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)Nov 6, 2017
    month 106 — 5× the typical 20-month injectable shortage
  • In shortage now — Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)Nov 6, 2017
    month 106 — 5× the typical 20-month injectable shortage
  • In shortage now — Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)Nov 6, 2017
    Other
    month 106 — 5× the typical 20-month injectable shortage

Recalls (this NDC)

  • Class II · OngoingMay 28, 2025
    Pfizer Inc. — Discoloration; discolored solution from cracked vials
  • Class I · TerminatedJan 10, 2014
    Hospira Inc. — Presence of Particulate Matter: Discolored solution due to a chip in the glass at the neck of the vial, also glass particulate was found within the solution.

Manufacturers of Dobutamine (Injection, Solution, Concentrate)

LabelerStrengthFirst seenLast seen
Hospira, Inc.DOBUTAMINE HYDROCHLORIDE 12.5 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstDOBUTAMINE HYDROCHLORIDE 12.5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Dobutamine — NDC 00409-2344-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00409234402.

Free to cite with attribution — see how the data is put together.